News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Hepatitis C treatment
Roche’s Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older

Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus.

Published
19 March 2013
From
Roche press release
Access to medicines and treatment
Athens urged to import generic drugs

Public health advocates are petitioning the Greek government to overturn patent protection on costly medicines and import them from low-cost generic producers to ease the burden on the country’s medical system.

Published
18 March 2013
From
Financial Times
Pharmaceutical industry
GlaxoSmithKline boss says new drugs can be cheaper

The pharmaceutical industry should be able to charge less for new drugs in future by passing on efficiencies in research and development to its customers, according to the chief executive of GlaxoSmithKline Plc.

Published
18 March 2013
From
Reuters
Lipodystrophy
Health Canada rejects tesamorelin for lipodystrophy

After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

Published
13 March 2013
From
Theratechnologies press release
Pharmaceutical industry
Pfizer stops developing hepatitis C drug

Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

Published
10 March 2013
From
EATG
Access to medicines and treatment
U.S. “Stalling” Could Force Acceptance of Onerous TPP

Civil society opposition here has strengthened against a U.S.-proposed free trade zone that would include some dozen countries around the Pacific Rim. As negotiators head into a 16th round of talks this week in Singapore, around 400 organisations are urging the U.S. Congress to demand greater transparency in the proceedings.

Published
05 March 2013
From
Inter Press Service
Access to medicines and treatment
India board rules against Bayer in cancer drug patent case

An Indian patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.

Published
05 March 2013
From
Chicago Tribune
Health monitoring in resource-limited settings
Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis & Expand Manufacturing for POC HIV Viral Load Platform

Alere Inc. announced that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill & Melinda Gates Foundation to support development of a point-of-care nucleic acid test for tuberculosis and to expand production facilities for this test and for a point-of-care viral load test.

Published
02 March 2013
From
Alere
Access to medicines and treatment
India May Drop Compulsory Licenses Based On Price

India’s Department of Pharmaceuticals this week issued a new draft guidance that says once patented drugs come under proposed price controls, the cost of these medicines should be considered reasonable and compulsory license should not be issued based on affordability.

Published
02 March 2013
From
Pharmalot
Access to medicines and treatment
Detailed analysis of the Medicines Patent Pool-ViiV pediatric ARV license and memorandum of understanding

This License Agreement and its subsidiary Sublicense Agreement will be a presumptive template for pediatric access to all of ViiV's current pipeline ARVs once they are approved by for use by the US Food and Drug Administration (FDA) or by the European Medicines Authority (EMA).   On February 27, the Medicines Patent Pool (MPP) and ViiV Healthcare UK Limited (ViiV) announced their License Agreement on an older antiretroviral (ARV), abacavir (ABC), for pediatric treatment only, in 118 countries where 98.7% of child living with HIV live.  They also entered into a separate, non-binding Memorandum of Agreement (MoU),...

Published
01 March 2013
From
EATG
← First12345...49Next →

Filter by country